1,035 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by GYL Financial Synergies LLC

GYL Financial Synergies LLC acquired a new position in United Therapeutics Co. (NASDAQ:UTHR) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 1,035 shares of the biotechnology company’s stock, valued at approximately $330,000.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC boosted its holdings in United Therapeutics by 176.2% in the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in United Therapeutics by 19.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares during the last quarter. International Assets Investment Management LLC lifted its position in United Therapeutics by 13,769.2% during the 4th quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock worth $1,982,000 after acquiring an additional 8,950 shares during the last quarter. BNP Paribas Financial Markets lifted its position in United Therapeutics by 90.3% during the 4th quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock worth $12,200,000 after acquiring an additional 26,325 shares during the last quarter. Finally, Comerica Bank lifted its position in United Therapeutics by 5.9% during the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after acquiring an additional 9,244 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

United Therapeutics stock traded up $0.01 during trading hours on Friday, hitting $346.88. 5,054 shares of the stock were exchanged, compared to its average volume of 497,244. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $353.49. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The business’s 50-day moving average is $323.09 and its two-hundred day moving average is $271.60. The stock has a market capitalization of $15.43 billion, a P/E ratio of 16.40, a P/E/G ratio of 1.16 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. During the same period last year, the company earned $5.24 earnings per share. United Therapeutics’s revenue for the quarter was up 19.8% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Co. will post 24.79 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on UTHR shares. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Oppenheimer boosted their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Morgan Stanley lowered shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. Finally, UBS Group upped their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $334.45.

Insider Activity

In other news, Director Raymond Dwek sold 5,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the sale, the director now directly owns 1,750 shares of the company’s stock, valued at $569,362.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other United Therapeutics news, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the transaction, the director now directly owns 1,750 shares of the company’s stock, valued at $569,362.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $269.06, for a total transaction of $968,616.00. Following the completion of the transaction, the director now directly owns 130 shares in the company, valued at $34,977.80. The disclosure for this sale can be found here. Insiders have sold 122,266 shares of company stock valued at $38,604,580 over the last three months. 12.50% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.